Return on Investments: An indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity. Calculated as: Income from Continuing Operations / (Total Long-Term Debt + Shareholders Equity)
Spyre Therapeutics, Inc. (SYRE) had Return on Investments of -40.17% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-208.02M |
|
-- |
|
-- |
|
$208.57M |
|
$-208.57M |
|
$0.60M |
|
$-207.97M |
|
$-207.97M |
|
$-208.02M |
|
$-208.02M |
|
$-208.02M |
|
$-208.02M |
|
$-208.57M |
|
$-219.97M |
|
47.03M |
|
47.03M |
|
$-4.42 |
|
$-4.42 |
|
| Balance Sheet Financials | |
$608.47M |
|
-- |
|
$0.01M |
|
$608.48M |
|
$54.06M |
|
-- |
|
$36.62M |
|
$90.68M |
|
$361.98M |
|
$517.80M |
|
$517.80M |
|
60.26M |
|
| Cash Flow Statement Financials | |
$-157.41M |
|
$-353.29M |
|
$410.91M |
|
$189.22M |
|
$89.42M |
|
$-99.79M |
|
$44.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.26 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-157.41M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-57.47% |
|
-40.17% |
|
-34.19% |
|
|
Return on Investments |
-40.17% |
$8.59 |
|
$-3.35 |
|
$-3.35 |
|